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Exploring the current role and future role of the pharmacists in osteoporosis screening 1 
and management in Malaysia.  2 
 3 
Introduction 4 
Osteoporosis inflicts a substantial burden on public health and national economies on the account of fragility 5 
fractures that results from the condition [1]. By year 2050, 50% of hip fractures worldwide will occur in Asia 6 
[2]. As such, it is imperative to conduct an intervention for the early detection and treatment of patients at risk 7 
[1]. 8 
 9 
The pharmacy profession has shifted from a product-centred approach to a more patient-oriented approach, 10 
which requires more direct interventions and involvement by the pharmacist going beyond medication 11 
dispensing [3]. This practice change has led to more intervention by pharmacists [4-7]. There is a growing body 12 
of literature supporting the roles of pharmacists in osteoporosis [4-8]. Studies conducted in various settings 13 
around the globe have shown that these pharmacists’ interventions improved adherence to osteoporosis 14 
medication. Some studies have also reported improvements in both clinical and economic outcome [4-7].  15 
 16 
Most pharmaceutical care services are mainly targeted at the treatment of osteoporosis. A further literature 17 
search revealed that there are three randomized control trials (RCTs) conducted overseas by community 18 
pharmacies to evaluate the impact of pharmacist’s interventions on osteoporosis management [9-11]. However, 19 
two of these studies were considered biased [12]. The study by Crockett et al had a high risk of both selection 20 
and information bias as self-reported assessment was used [10, 12]. As for the study by McDonough et al the 21 
study suffered from a high risk of selection bias as the recruitment size and followed up differed between groups 22 
[11, 12]. The third study by Yuksel et al demonstrated low bias in both aspects [9, 12]. Nonetheless, all three 23 
studies provided attestation that the intervention of pharmacists increased the number of patients that had their 24 
BMD tested and calcium intake initiated, indicating that pharmacists may have a role to play in reducing the gap 25 
in osteoporosis management [9-11].  26 
 27 
Foundational research on the pharmacist role in osteoporosis screening and management in the literature is 28 
sparse. Integrating a pharmacist into osteoporosis screening and management is a novel concept and requires a 29 
new model of practice to be explored. As such, investigating the perspective of key stakeholders on the 30 
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pharmacists’ role in osteoporosis screening and management is potentially crucial to the successful 31 
implementation of this concept. To date, there have been no studies on a pharmacist-led osteoporosis screening 32 
programme in Malaysia. This study explores the perspective of stakeholders such as policy makers, doctors, 33 
pharmacists, nurses and patients towards the role of pharmacists in osteoporosis screening and management.  34 
 35 
Aim of the study 36 
The aim of this study was to explore the perspective of stakeholders such as policy makers, doctors, 37 
pharmacists, nurses and patients towards the role of pharmacists in osteoporosis screening and management.  38 
 39 
Ethics approval 40 
Ethical approval was obtained from the University Malaya Medical Centre Ethics Committee (approval number: 41 
914.14). 42 
 43 
Method 44 
Qualitative, semi-structured in-depth interviews were used to allow for a detailed exploration of the perspective 45 
of stakeholders such as patients, nurses, doctors, pharmacists and policy makers on the role of the pharmacists in 46 
osteoporosis screening and management.  47 
 48 
This study was conducted at the primary care clinics located within a teaching hospital in Malaysia. The data 49 
was collected from October 2012 to January 2013. Participants were selected via purposive sampling. Non-50 
osteoporotic postmenopausal women ≥50 years of age from three main ethnics groups (Malays, Chinese, and 51 
Indians) in Malaysia were selected to account for any cultural differences. Healthcare professionals (pharmacist, 52 
primary care doctors, and nurses) with more than one year of working experience at the primary care clinic were 53 
selected as they would have sufficient working experience with the primary care clinic system. Policy makers 54 
were defined as individuals working in the upper management of the tertiary hospital. This includes head of 55 
departments who have an authority to influence and decide to change the practice 56 
 57 
Patients were recruited by approaching them in the primary care clinic while they were waiting for their doctors’ 58 
appointment. Patients’ medical records were screened to confirm that they did not have osteoporosis/osteopenia. 59 
Healthcare professionals and policy makers were recruited by approaching them personally and setting up 60 
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appointments for the interviews. The purpose of the study was explained to the participants using written 61 
information and consent was obtained.  62 
 63 
A topic guide was used to guide the interviews. Three topic guides were developed in English: one for patients, 64 
one for healthcare professionals and one for policy makers. The development of the topic guides was based on 65 
literature and an expert panel consisting of a consultant endocrinologist and four pharmacists. A translated topic 66 
guide was needed as some interviews were conducted in Malay. Forward and backward translation were 67 
conducted by two bilingual pharmacists who were not participants of this study. Differences were discussed 68 
using the expert panel. Each topic guide was piloted for finalization. 69 
 70 
All patients, healthcare professional and policy maker interviews were conducted by the researcher (LST), who 71 
was a pharmacist. However, this was not revealed to the participants until the interview had ended. Interviews 72 
lasted an average of 60 minutes and were conducted by a trained researcher in either English or Malay. All 73 
interviews were transcribed verbatim and checked by a second researcher/pharmacist for accuracy.  All 74 
transcripts were offered to each interviewee to check for accuracy but all declined. 75 
 76 
Data Analysis 77 
QSR International Pty Ltd. NVivo version 10 for Windows, 2012 was used to aid in the analysis of the data. 78 
Analysis began during data collection. At the end of each interview, the researcher wrote memos of interesting 79 
topics that were raised in the interview. The data analysis was data-driven. 80 
 81 
Thematic analysis was used to analyze the interview data [13, 14]. It involves analyzing the data as a whole to 82 
find repeated patterns of meaning [13, 14]. The analysis of the data involved repeatedly reading the transcripts 83 
while listening to the audio recording, and emerging topics were coded and constantly compared and contrasted 84 
with other transcripts by one researcher developing a coding framework [13].  85 
 86 
The ‘one sheet of paper’ (OSOP) analysis as described by Ziebland and McPherson (2006) was then used to 87 
progress the analysis of the data. Emerging themes were then refocused at a broader level of themes [13]. This 88 
involved sorting the themes into broader themes and collating all the relevant coded data extracts within the 89 
identified theme. OSOP involved reading through each code and then noting on a piece of paper all issues that 90 
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were raised and making connections between them [15]. This process allowed identification of deviant cases 91 
that did not fit into the emerging story. These deviant cases were then reanalyzed and accounted for in the 92 
analysis [16]. Data saturation was reached when no new codes emerged when new participants were recruited 93 
into the study [17].  94 
 95 
The analysis of each stakeholder: patients, pharmacists, nurses, doctors and policy makers were conducted 96 
separately. However, the themes which emerged within each group of stakeholder were similar and the analysis 97 
were combined. As a form of validation, a subset of transcripts was reviewed by two other members of the 98 
research team for agreement of the codes and themes. 99 
 100 
For verification purposes, all transcripts were translated to English. However, the original language was used 101 
during data analysis. Analyzing in the original language facilitated cross checking the data with the audio 102 
recordings.  During data analysis, selected themes and sub-themes from the Malay language were translated to 103 
English. The study by Chen & Boore supports that verbatim transcripts and data analysis to be conducted in the 104 
original language and only emergent concepts, themes and sub-themes needed translation to English [18]. 105 
 106 
Results 107 
Fifty-six participants were interviewed (patients = 20, nurses = 10, pharmacists = 11, doctors = 10 and 108 
policymakers = 5). Each interview lasted an average of 60 min. Patients interviewed were 52-72 years of age. 109 
Six patients were Malay, six were Indians, and eight were Chinese. All nurses had four years or more of 110 
working experience. Pharmacists' work experience ranged from 2 to 4 years, whilst doctors' work experience 111 
ranged from 3 to 4 years. 112 
 113 
Most of the interviews were conducted in English, sixteen patients' interviews, two nurses' interviews, nine 114 
pharmacists' interviews, and four doctors. Two patient interviews, eight nurses' interviews, two pharmacist 115 
interviews and five interviews with policy makers were conducted in both English and Malay. Two patient 116 
interviews were conducted in Malay. 117 
 118 
The results were divided to two sections: the current role of the pharmacists and the future role of the 119 
pharmacists in osteoporosis screening and management 120 
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 121 
The current perceived role of the pharmacists in practice 122 
Pharmacists were principally perceived by participants to be suppliers of medication, although there was some 123 
recognition of roles in providing medication safety, medication costing and medication advice [Table 1]. 124 
 125 
Table 1: Summary of current perceived pharmacists’ role by patients, nurses, doctors, pharmacists and policy 126 
makers 127 
Current perceived pharmacists role Sub themes 
Suppliers of medication Dispensing of medications 
Approval of medication supply 
Medication safety Ensure patients receives the appropriate medications 
Medication advice Medication advice to patients 
Medication advice to other healthcare professionals 
Medication costing Budgeting of  medication fund 
 128 
Suppliers of medication 129 
Dispensing medications 130 
The supplying of medications by dispensing was seen to be the core duty of the pharmacists. Dispensing was 131 
perceived to be an activity where the pharmacists receives a prescription from the patients at the counter and 132 
supplies the appropriate medication. If it is a repeated prescription, the pharmacists would set another 133 
appointment date for the patients to collect the medication. 134 
 135 
“So I take the (medication from the pharmacist for the) first time... (then) they give me another date to, 136 
replenish... (my medication in about) six months or one year... appointment. That’s all...”   137 
         (Patient-16/Female/70 years) 138 
 139 
Approval of medication supply 140 
Additionally, the supplying of medications also refers to the pharmacists’ role in the hospital’s Drugs and 141 
Therapeutics sub-committee whereby policies about medication usage are determined. Various policies are 142 
approved to only allow certain group of specialist to prescribe certain medications. For example, osteoporosis 143 
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medications can only be dispensed if a bone mineral densitometry (BMD) scan indicates osteoporosis and if it is 144 
prescribed by endocrinologists, orthopaedics and gynaecologists. Therefore, the pharmacists would need to 145 
ensure the appropriate forms and procedures are conducted before the medication can be dispensed to the 146 
patients.  147 
 148 
“So the pharmacists will assess if the patients can get the medication for free, whether the doctor can prescribe 149 
the medication or not. Because previously, Fosamax we had to attach the BMD report.”  150 
(Nurse-9/Female/42 years) 151 
 152 
Medication safety 153 
Ensure patients receives the appropriate medication 154 
The pharmacists were seen to be the final safety net before the patients take home their medications. As the 155 
primary care clinic has a lot of trainee doctors, the pharmacists’ role to ensure that the patients receive the 156 
appropriate medication is crucial. To elaborate on this, the pharmacists play an important role to check the 157 
appropriateness of the medication in terms of the indication, dose and interaction. 158 
 159 
“... At the moment the role... (is) making sure that... the med(ication), the patient is receiving is safe... The main 160 
focus is safety... whatever prescription that come in... (we ensure the) dose, the combination of products... is safe 161 
for the patient(s)...”      (Pharmacist-8/Female/29 years) 162 
 163 
Medication advice 164 
Medication advice to patients  165 
The pharmacists were also recognised for their role in giving medication advice. The pharmacists would 166 
dispense the medications and provide information to the patients regarding the medications. The information 167 
provided includes the indication, mode of action, side effects and method of taking the medications. The 168 
monitoring of the patients adherence and compliance is also part of this process. There were some patients who 169 
recognized the pharmacists’ role in advice for minor ailments and supplements.  170 
 171 
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“Pharmacist, I think it’s very important... the role would be to explain to the patients regarding the indication of 172 
the medication, the mode of action and the proper way of taking the medications.”   173 
         (Doctor-3/Female/36 years) 174 
 175 
Medication advice to other healthcare professionals 176 
Apart from that, pharmacists were seen by the other healthcare professionals such as doctors and nurses to be 177 
medication experts. They would seek advice from the pharmacists regarding: side effects, interactions, dosage, 178 
approval to prescribe and availability. However; this is not a common occurrence.  179 
 180 
“But for me... the pharmacist relationship is... just to ask about the drugs side effects, the drugs whether (it) can 181 
be prescribe, about the dosage, everything...”     (Doctor-8/Female/29 years) 182 
 183 
Medication costing 184 
Budgeting of medication fund 185 
Pharmacists were seen to be involved in medication costing via the hospital’s Drugs and Therapeutics sub-186 
committee. The policy to only allow certain groups of specialist to prescribe certain medications is part of fund 187 
management. Due to the shortage of funds there was a shortage of medications. Hence, pharmacists at the upper 188 
management level would need to develop policies to ensure sufficient medication is available where else 189 
pharmacists at the frontline would need to ensure these policies are adhered too.  190 
 191 
 “(This policy is to) save cost because we have to ensure that the usage of the medication is not too high. Hence, 192 
we limited it to a certain amount of patients (whom are under the specialists’ care). Therefore, we are forced to 193 
do screening of prescribed medication this way.”    (Policy maker-5/Male/44 years) 194 
 195 
The perceived future role of the pharmacists in osteoporosis screening and management 196 
Doctors, nurses, patients, policy makers and pharmacists themselves were eager for pharmacists to expand their 197 
role beyond medication: supply, advice, costing and safety. The stakeholders perceived that the pharmacists 198 
should expand their role in terms of counselling, creating awareness and screening of osteoporosis [Table 2].  199 
 200 
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“But I think we are actually well position to actually do... this screening and in fact to do the counsel(ing) (and) 201 
educating the public.”      (Policy maker-2/Female/51 years) 202 
 203 
Table 2: Summary of perceived future pharmacists’ role by patients, nurses, doctors, pharmacists and policy 204 
makers 205 
Perceived future pharmacists role 
Counselling 
Creating osteoporosis awareness 
Screening of osteoporosis 
 206 
Counselling 207 
Counselling was seen to be conducting activities such as the current medication therapy adherence and 208 
compliance (MTAC) clinic conducted for diabetic patients. This was an individualized service provided by the 209 
pharmacists. Pharmacists assist the patients in adjusting their insulin dose and give lifestyle advice. 210 
Recommendations to doctor regarding therapy were also given if necessary. However, this service is only 211 
conducted for diabetics and patients on warfarin. Therefore, stakeholders noted the possibility of this kind of 212 
services to be extended to osteoporosis and other diseases. Additionally, group counselling by the pharmacists 213 
was also suggested.  214 
 215 
“I want the MTAC [clinic for] osteoporosis to be implemented again in our hospital after proper planning... 216 
because...  from here we can... reach out to the public because... my daily job. I think (it) is very... difficult for 217 
me to actually talk to them (patients).”     (Pharmacist-10/Female/28 years) 218 
 219 
Creating awareness of osteoporosis 220 
The second area suggested was creating awareness on osteoporosis and public health in general. Stakeholders 221 
suggest various ways such as creating posters, campaigns or giving health talks during clinic session. However, 222 
this could also be done opportunistically. For example, pharmacists could casually mention to a postmenopausal 223 
women if she has undergone a BMD scan. Pharmacists were seen to be most accessible to patients at the 224 
community level. Therefore, pharmacists are in an ideal position to create awareness on osteoporosis and 225 
various diseases.  226 
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 227 
“I think they (primary care pharmacists) have (a) big role because... they are more... involved with community... 228 
they have a major role in screening, not only osteoporosis, other diseases as well. And then to educate patients 229 
also, they have... a big role.”     (Doctor-5/Male/30 years) 230 
 231 
Screening of osteoporosis  232 
Lastly, the pharmacists were seen to be in an ideal position to screen for osteoporosis. This is because 233 
pharmacists were seen to be more accessible. Patients would visit the pharmacists several times before their next 234 
doctor’s appointment for their repeat prescriptions. This gives the pharmacists the opportunity to tap into 235 
screening and prevention of osteoporosis. Patients also perceived pharmacists to be knowledgeable and trust 236 
pharmacist for advice. 237 
 238 
“Pharmacist can explain to us... rheumatism (referring to osteoporosis)...  what you (kind of supplements to) 239 
take... we.... trust the pharmacist.”    (Patient-6/Female/72 years) 240 
 241 
Currently, both the doctors and nurses are unable to screen for osteoporosis systematically due to the time 242 
constraint. If pharmacists were involved in osteoporosis screening it was seen as an improvement to the 243 
healthcare system. This facilitates the healthcare professionals to understand each others’ scope of practice 244 
better leading to a more effective healthcare system. Additionally, the involvement of pharmacists in 245 
osteoporosis screening would lighten the workload of doctors and nurses. This in turn saves both the patients 246 
and healthcare professionals’ time. The pharmacist would screen for osteoporosis and the doctors would focus 247 
on diagnosis and treatment.  Hence, the pharmacists could play a part in osteoporosis screening alerting the 248 
doctors when a BMD scan may be needed. This will assists in detecting untreated osteoporosis. 249 
 250 
“...Pharmacist can help to save (the) doctor’s time... because some patient(s) (do not) need to (be) referred (to 251 
the) doctor. Waste both... (the) doctors’ and patients’ time... So if (the) pharmacists can do that (osteoporosis 252 
screening), it’s good.”       (Pharmacist-2/Female/24 years)  253 
  254 
 Interviewed pharmacists referred to their current role as ‘robotic dispensers’ and unanimously agreed for an 255 
expansion of the pharmacist role in osteoporosis screening. They felt that they weren’t contributing enough to 256 
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the society and were not satisfied with their current job scope. Therefore, there is a need to expand the 257 
pharmacist non-dispensing role in osteoporosis screening. 258 
 259 
“(We) dispense like (a) robot...  you just push, push, push the thing (medication) out.”   260 
(Pharmacist-6/Female/27 years) 261 
 262 
Lastly, all the participants concurred that the expansion of the non-dispensing role of the pharmacists to 263 
osteoporosis screening was seen as progression for the profession. The pharmacists’ skills were considered 264 
underutilized and shifting from a more medication-centred approach to a more patient-orientated approach was 265 
suggested. This emphasizes the need to expand the pharmacists’ role to osteoporosis screening. Additionally, 266 
pharmacists were well equipped with the knowledge on the disease, treatment and prevention.  Stakeholders 267 
noted the success of pharmacists’ independent prescribing role overseas such as in the UK. They unanimously 268 
agreed that the pharmacists’ role should be expanded to osteoporosis management. 269 
 270 
“(The pharmacists’) job scope is expanding all this time… I wouldn’t be surprised if pharmacist (start) 271 
screening (for osteoporosis) since (there are) all ready… pharmacist prescribers (overseas)...”   272 
        (Pharmacist-11/Female/28 years) 273 
 274 
Discussion 275 
The semi-structured interviews outlined above gives us a unique insight into the opinions and views of policy 276 
makers, doctors, pharmacist, nurses and patients around the current role of pharmacist in Malaysia and 277 
perspective of their future role in osteoporosis management. These stakeholders perceived the current 278 
pharmacist role to be medication centred: medication supplier, medication advice, medication safety and 279 
medication costing. However, the doctors, nurses, patients, policy makers and pharmacists themselves were 280 
eager for pharmacists to expand their role beyond medication to more patient centred such as counselling, 281 
creating awareness and screening of osteoporosis. 282 
 283 
This concurs with the general progress of the pharmacy profession where the traditional role of pharmacists 284 
such as dispensing and compounding of medication shifts to a strengthening role of providing medication 285 
information as well as improving the quality use of medication activities such as medication management 286 
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reviews and chronic disease management programs [19]. In Australia, pharmacists are viewed as highly trained 287 
yet underutilised and there is growing support to extend the role of pharmacist within the primary health care 288 
sector [20]. Similarly, the stake holders cited that pharmacists were seen to be more accessible to screen for 289 
osteoporosis and that they were underutilized.  290 
 291 
Recent research on the expansion of the pharmacist role has shown positive response from general practitioners 292 
recognising the potential benefit of integrating a pharmacist into the medical team with the recognised benefits 293 
perceived by the general practitioners increasing over time [21-23]. A systematic review in 2014, revealed that 294 
pharmacist co-located in general practice clinics could deliver favourable results when conducting chronic 295 
disease clinics and quality use of medicines reviews, resulting in improved clinical outcomes such as blood 296 
pressure, blood sugar and cholesterol reduction [24]. Research also found that patients are generally supportive 297 
of a pharmacist involvement in non-dispensing roles [25].  298 
 299 
Our study noted that one of the pharmacist future role could be to create awareness of osteoporosis. This was a 300 
similar finding from another Malaysian study exploring community pharmacist role in type two diabetes 301 
management. However, creating awareness of diabetes was a role that the pharmacist was currently conducting 302 
[26]. As such, there is a potential for pharmacists to create awareness in osteoporosis as well as other chronic 303 
diseases such as diabetes. 304 
 305 
Additionally, our study also found that Malaysian pharmacists were minimally involved in osteoporosis 306 
management. These findings were similar to another Malaysian study in community pharmacists where the 307 
pharmacists appeared to be rooted in the traditional role of medication dispensing but recognizing the potential 308 
to expend their roles. In that study, only ad-hoc counselling, such as advice on osteoporosis prevention, risk 309 
factors and lifestyle medication was practiced [27]. Our interviewed pharmacists referred to their current role as 310 
‘robotic dispensers’ and unanimously agreed for an expansion of the pharmacist role in osteoporosis screening. 311 
The themes from this study resonates with the themes that emerged from other studies. The Canadian survey 312 
reported that although pharmacists spend most of their time on dispensing duties but over 60% believed that the 313 
time had come to expand their role in areas such as disease prevention and health promotion [28]. 314 
 315 
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The interpretation of the results may be limited to the confined area where the participants were recruited. As 316 
such, this qualitative research was then able to reflect on the local setting and are not generalizable to other 317 
setting. Nonetheless, the themes generated resonated with themes that occurred in other studies. Another 318 
limitation of the study is that the interviews were only conducted in Malay or English, which are the two main 319 
languages, spoken in Malaysia. Interviews were not conducted in Mandarin or Tamil, as those proficient in 320 
Mandarin or Tamil would also be able to speak in English or Malays. Although, the data was not analysed 321 
independently by two researchers, sections of the coded transcripts were presented to two researchers on 322 
separate occasions to establish if other members of the research team agreed with the themes assigned. 323 
Discussions were conducted until a consensus was reached. Additionally, the healthcare professionals had 324 
varying years of working experiences ranging from two to four years for doctors and pharmacists and more than 325 
four years for nurses. However, their views towards the pharmacists role were similar.  326 
 327 
The strength of this study is that the sample comprised of a purposive sample of healthcare professionals and 328 
consumers involved in the primary care setting. Hence, we were able to gain an in depth understanding of the 329 
perceived current and future role of the pharmacist in osteoporosis screening and management. Another strength 330 
of this study is that it used qualitative methods to contribute to the currently sparse literature on stakeholders’ 331 
perception towards the pharmacists’ role in osteoporosis screening and management. The findings from this 332 
study has the potential to highlight the successful integration of the non-dispensing role of the pharmacist in 333 
osteoporosis screening and management through an understanding of the current position of the pharmacist and 334 
the expected direction of the pharmacy profession. Future studies should focus on developing and integrating 335 
the non-dispensing pharmacist role into daily clinical practice and then assessing for effectiveness. 336 
 337 
Conclusion 338 
Although the current role of pharmacists in Malaysia is medication-centred, healthcare professionals and 339 
consumers are willing to expand it to non-dispensing roles, in particular to osteoporosis screening and 340 
management. This encourages further efforts to examine the potentially missed opportunities for Malaysian 341 
pharmacist to assume an expanded role in health care.  342 
 343 
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